LOGIN  |  REGISTER
Terns Pharmaceuticals
Compass Therapeutics

So-Young Reports Unaudited Third Quarter 2024 Financial Results

November 20, 2024 | Last Trade: US$0.78 0.01 1.31

BEIJING, Nov. 20, 2024 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the third quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights

  • Total revenues were RMB371.8 million (US$53.0 million[1]), compared with RMB385.3 million in the corresponding period of 2023, exceeding the high end of guidance.
  • Net income attributable to So-Young International Inc. was RMB20.3 million (US$2.9 million), compared with net income attributable to So-Young International Inc. of RMB18.3 million in the same period of 2023.
  • Non-GAAP net income attributable to So-Young International Inc.[2] was RMB22.2 million (US$3.2 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB9.5 million in the same period of 2023.

Third Quarter 2024 Operational Highlights

  • Average mobile MAUs were 1.4 million, compared with 3.1 million in the third quarter of 2023.
  • Number of medical service providers subscribing to information services on So-Young's platform was 1,322, compared with 1,397 in the third quarter of 2023.
  • Total number of purchasing users through reservation services was 114.9 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young's platform was RMB346.0 million.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, said, "Our third quarter performance beat the high end of our guidance once again, highlighting the resilience of our business. Sales of medical products and maintenance services grew by 18.7% year-over-year, becoming a key growth driver contributing to a year-over-year increase in net income. This underscores the effectiveness of our strategy to stay at the forefront of industry trends by deepening the synergies from our vertical integration and continuously diversifying our offerings. Our clinic network has experienced significant growth. The number of stores has grown to 16 by the end of this quarter, extending our presence into additional major cities. All stores are situated in central business districts, enhancing our market coverage and competitive position. To further scale our offline presence, we are accelerating the deployment of this proven standardized model in other cities nationwide and are exploring franchising opportunities to engage with a wider audience. The reputational strength of our brand and our deep understanding of evolving consumer behavior uniquely position us to develop products that resonate with consumer needs. Sales momentum remains robust, driven by both our well-established products and exciting new launches in collaboration with our supply chain partners. Looking ahead, we are committed to seizing opportunities across the entire medical aesthetics value chain while deepening the integration of our three core businesses to maximize operational efficiency, customer satisfaction, and sustainable growth."

Mr. Hui Zhao, Chief Financial Officer of So-Young, added, "Our third-quarter results reflect our ability to strategically adapt to changing market dynamics. Through disciplined cost management and targeted growth initiatives, we are carefully navigating this challenging market environment while building a solid foundation for future expansion. Encouragingly, our net income and non-GAAP net income attributable to So-Young International Inc. improved significantly, with year-over-year growth rates exceeding 8.9% and 133.1% respectively. Looking ahead, we will leverage our expanding network of clinics and meticulously curated product offerings to address the growing demand for high-quality solutions and services. By maintaining operational efficiency and scalability, we are well-positioned to continue leading the medical aesthetics sector, delivering sustainable growth and long-term value for our shareholders."

[1] This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.0176 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on September 30, 2024.

[2] Non-GAAP net income attributable to So-Young International Inc. is defined as net income attributable to So-Young International Inc. excluding share-based compensation expenses attributable to So-Young International Inc. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

Third Quarter 2024 Financial Results     

Revenues

Total revenues were RMB371.8 million (US$53.0 million), a decrease of 3.5% from RMB385.3 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.

  • Information services and other revenues were RMB263.0 million (US$37.5 million), a decrease of 8.0% from RMB285.9 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.
  • Reservation services revenues were RMB19.6 million (US$2.8 million), a decrease of 18.9% from RMB24.1 million in the same period of 2023. The decrease was primarily due to a decrease in consumer spending through our platform.
  • Sales of medical products and maintenance services were RMB89.3 million (US$12.7 million), an increase of 18.7% from RMB75.2 million in the same period of 2023, primarily due to an increase in the order volumes for cosmetic products and medical equipment.

Cost of Revenues

Cost of revenues was RMB142.2 million (US$20.3 million), a decrease of 0.3% from RMB142.6 million in the third quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with the information services. Cost of revenues included share-based compensation expenses of RMB0.1 million (US$0.0 million), compared with the share-based compensation expenses of RMB0.4 million in the corresponding period of 2023.

  • Cost of services and others were RMB98.6 million (US$14.1 million), a decrease of 4.7% from RMB103.5 million in the third quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with the information services.
  • Cost of medical products sold and maintenance services were RMB43.5 million (US$6.2 million), an increase of 11.3% from RMB39.1 million in the third quarter of 2023. The increase was primarily due to an increase in costs associated with the sales of cosmetic products.

Operating Expenses

Total operating expenses were RMB225.0 million (US$32.1 million), a decrease of 8.1% from RMB244.7 million in the third quarter of 2023.

  • Sales and marketing expenses were RMB114.9 million (US$16.4 million), a decrease of 20.1% from RMB143.8 million in the third quarter of 2023. The decrease was mainly due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with RMB0.5 million in the corresponding period of 2023.
  • General and administrative expenses were RMB69.9 million (US$10.0 million), an increase of 39.1% from RMB50.2 million in the third quarter of 2023. The increase was primarily due to an increase in share-based compensation expenses. General and administrative expenses included share-based compensation expenses of RMB1.3 million (US$0.2 million), compared with a reversal of share-based compensation expenses of RMB11.2 million in the corresponding period of 2023.
  • Research and development expenses were RMB40.2 million (US$5.7 million), a decrease of 20.6% from RMB50.6 million in the third quarter of 2023. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses included share-based compensation expenses of RMB0.3 million (US$0.0 million), compared with RMB1.5 million in the corresponding period of 2023.

Income Tax (Expenses)/Benefits

Income tax expenses were RMB2.1 million (US$0.3 million), compared with income tax benefits of RMB2.2 million in the same period of 2023.

Net Income Attributable to So-Young International Inc.

Net income attributable to So-Young International Inc. was RMB20.3 million (US$2.9 million), compared with a net income attributable to So-Young International Inc. of RMB18.3 million in the third quarter of 2023.

Non-GAAP Net Income Attributable to So-Young International Inc.

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses attributable to So-Young International Inc., was RMB22.2 million (US$3.2 million), compared with RMB9.5 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2023.

Basic and Diluted Earnings per ADS

Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.20 (US$0.03) and RMB0.20 (US$0.03), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.18 and RMB0.18, respectively, in the same period of 2023.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of September 30, 2024, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,252.6 million (US$178.5 million), compared with RMB1,341.6 million as of December 31, 2023.

Business Outlook

For the fourth quarter of 2024, So-Young expects total revenues to be between RMB350.0 million (US$49.9 million) and RMB370.0 million (US$52.7 million), representing a 10.4% to 5.3% decrease from the same period in 2023. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income attributable to So-Young International Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young's management will hold an earnings conference call on Wednesday, November 20, 2024, at 7:00 AM U.S. Eastern Time (8:00 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

International:

+1-412-902-4272

Mainland China: 

4001-201203

US:

+1-888-346-8982

Hong Kong:

+852-301-84992

Passcode: 

So-Young International Inc.

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, November 27, 2024. The dial-in details are:

International: 

+1-412-317-0088

US:

+1-877-344-7529

Passcode:

2642052

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young's strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. 

Christensen

In China
Ms. Dee Wang
Phone: +86-10-5900-1548
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. 

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except for share and per share data)

 
 

As of

 

December 31,

 

September 30,

 

September 30,

2023

2024

2024

 

RMB

 

RMB

 

US$

Assets

     

Current assets:

     

Cash and cash equivalents

426,119

 

467,407

 

66,605

Restricted cash and term deposits

14,695

 

104,198

 

14,848

Trade receivables

57,219

 

106,943

 

15,239

Inventories

118,924

 

145,601

 

20,748

Receivables from online payment platforms

23,158

 

31,666

 

4,512

Amounts due from related parties

9,212

 

10,466

 

1,491

Term deposits and short-term investments

900,823

 

681,035

 

97,047

Prepayment and other current assets

171,774

 

221,227

 

31,525

Total current assets

1,721,924

 

1,768,543

 

252,015

Non-current assets:

     

Long-term investments

261,016

 

287,507

 

40,969

Intangible assets

145,253

 

131,641

 

18,759

Goodwill

540,693

 

540,693

 

77,048

Property and equipment, net

116,782

 

154,572

 

22,026

Deferred tax assets

78,034

 

81,057

 

11,551

Operating lease right-of-use assets

118,408

 

159,179

 

22,683

Other non-current assets

232,455

 

180,628

 

25,739

Total non-current assets

1,492,641

 

1,535,277

 

218,775

Total assets

3,214,565

 

3,303,820

 

470,790

      

Liabilities

     

Current liabilities:

     

Short-term borrowings

29,825

 

89,559

 

12,762

Taxes payable

56,894

 

53,639

 

7,643

Contract liabilities

103,374

 

94,747

 

13,501

Salary and welfare payables

86,290

 

84,927

 

12,102

Amounts due to related parties

388

 

146

 

21

Accrued expenses and other current liabilities

233,913

 

244,721

 

34,873

Operating lease liabilities-current

29,739

 

40,398

 

5,757

Total current liabilities

540,423

 

608,137

 

86,659

Non-current liabilities:

     

Operating lease liabilities-non current

86,210

 

124,915

 

17,800

Deferred tax liabilities

25,082

 

20,780

 

2,961

Other non-current liabilities

1,536

 

1,607

 

229

Total non-current liabilities

112,828

 

147,302

 

20,990

Total liabilities

653,251

 

755,439

 

107,649

      
 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)

(Amounts in thousands, except for share and per share data)

 

Shareholders' equity:

     

Treasury stock

(358,453)

 

(369,907)

 

(52,711)

Class A ordinary shares (US$0.0005 par value; 750,000,000
     shares authorized as of December 31, 2023 and September
     30, 2024; 73,688,044 and 63,422,436 shares issued and
     outstanding as of December 31, 2023, 77,634,580 and
     66,170,882 shares issued and outstanding as of September
     30, 2024, respectively)

238

 

252

 

36

Class B ordinary shares (US$ 0.0005 par value; 20,000,000
     shares authorized as of December 31, 2023 and September
     30, 2024; 12,000,000 shares issued and outstanding as of
     December 31, 2023 and September 30, 2024)

37

 

37

 

5

Additional paid-in capital

3,080,433

 

3,067,567

 

437,125

Statutory reserves

33,855

 

33,855

 

4,824

Accumulated deficit

(330,166)

 

(312,117)

 

(44,476)

Accumulated other comprehensive income

18,185

 

8,858

 

1,262

Total So-Young International Inc. shareholders' equity

2,444,129

 

2,428,545

 

346,065

Non-controlling interests

117,185

 

119,836

 

17,076

Total shareholders' equity

2,561,314

 

2,548,381

 

363,141

Total liabilities and shareholders' equity

3,214,565

 

3,303,820

 

470,790

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except for share and per share data) 

 
 

For the Three Months Ended

 

For the Nine Months Ended

 

September 
30
, 2023

 

September
30
, 2024

 

September
30
, 2024

 

September
30
, 2023

 

September
30
, 2024

 

September
30
, 2024

 
 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 
             

Revenues:

            

Information services and others

285,937

 

262,988

 

37,475

 

795,100

 

750,952

 

107,010

 

Reservation services

24,140

 

19,567

 

2,788

 

80,724

 

64,987

 

9,261

 

Sales of medical products and maintenance services

75,217

 

89,270

 

12,721

 

231,639

 

281,548

 

40,120

 

Total revenues

385,294

 

371,825

 

52,984

 

1,107,463

 

1,097,487

 

156,391

 

Cost of revenues:

            

Cost of services and others

(103,484)

 

(98,620)

 

(14,053)

 

(291,503)

 

(274,695)

 

(39,144)

 

Cost of medical products sold and maintenance services

(39,119)

 

(43,548)

 

(6,206)

 

(115,199)

 

(139,839)

 

(19,927)

 

Total cost of revenues

(142,603)

 

(142,168)

 

(20,259)

 

(406,702)

 

(414,534)

 

(59,071)

 

Gross profit

242,691

 

229,657

 

32,725

 

700,761

 

682,953

 

97,320

 

Operating expenses:

            

Sales and marketing expenses

(143,844)

 

(114,884)

 

(16,371)

 

(394,276)

 

(360,448)

 

(51,363)

 

General and administrative expenses

(50,242)

 

(69,901)

 

(9,961)

 

(204,097)

 

(225,653)

 

(32,155)

 

Research and development expenses

(50,597)

 

(40,188)

 

(5,727)

 

(158,531)

 

(122,277)

 

(17,424)

 

Total operating expenses

(244,683)

 

(224,973)

 

(32,059)

 

(756,904)

 

(708,378)

 

(100,942)

 

(Loss)/Income from operations

(1,992)

 

4,684

 

666

 

(56,143)

 

(25,425)

 

(3,622)

 

Other income/(expenses):

            

Investment income, net

647

 

510

 

73

 

10,869

 

3,397

 

484

 

Interest income, net

12,130

 

14,239

 

2,029

 

38,023

 

38,270

 

5,453

 

Exchange gains/(losses)

103

 

465

 

66

 

(1,051)

 

875

 

125

 

Share of losses of equity method investee

(3,822)

 

(3,873)

 

(552)

 

(10,692)

 

(11,602)

 

(1,653)

 

Others, net

9,887

 

6,915

 

985

 

18,474

 

12,234

 

1,743

 

Income/(Loss) before tax

16,953

 

22,940

 

3,267

 

(520)

 

17,749

 

2,530

 

Income tax benefits/(expenses)

2,191

 

(2,097)

 

(299)

 

7,240

 

3,031

 

432

 

Net income

19,144

 

20,843

 

2,968

 

6,720

 

20,780

 

2,962

 

Net income attributable to noncontrolling interests

(839)

 

(495)

 

(71)

 

(2,941)

 

(2,731)

 

(389)

 

Net income attributable to So-Young International Inc.

18,305

 

20,348

 

2,897

 

3,779

 

18,049

 

2,573

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)

(Amounts in thousands, except for share and per share data)

 
 

For the Three Months Ended

 

For the Nine Months Ended

 

September
30
, 2023

 

September
30
, 2024

 

September
30
, 2024

 

September
30
, 2023

 

September
30
, 2024

 

September
30
, 2024

 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

            

Net earnings per ordinary share

           

Net earnings per ordinary share attributable to ordinary shareholder - basic

0.24

 

0.26

 

0.04

 

0.05

 

0.23

 

0.03

Net earnings per ordinary share attributable to ordinary shareholder - diluted

0.24

 

0.26

 

0.04

 

0.05

 

0.23

 

0.03

Net earnings per ADS attributable to ordinary shareholders - basic (13 ADS
     represents 10 Class A ordinary shares)

0.18

 

0.20

 

0.03

 

0.04

 

0.18

 

0.03

Net earnings per ADS attributable to ordinary shareholders - diluted (13 ADS
     represents 10 Class A ordinary shares)

0.18

 

0.20

 

0.03

 

0.04

 

0.18

 

0.03

Weighted average number of ordinary shares used in computing earnings/(loss)
     per share, basic*

76,842,709

 

79,493,819

 

79,493,819

 

78,001,149

 

79,544,066

 

79,544,066

Weighted average number of ordinary shares used in computing earnings/(loss)
     per share, diluted*

77,210,781

 

79,708,518

 

79,708,518

 

78,402,636

 

79,810,666

 

79,810,666

            

Share-based compensation expenses included in:

           

Cost of services and others

(418)

 

(81)

 

(12)

 

(1,635)

 

(255)

 

(36)

Sales and marketing expenses

(533)

 

(183)

 

(26)

 

(2,850)

 

(420)

 

(60)

General and administrative expenses

11,164

 

(1,328)

 

(189)

 

(10,400)

 

(27,796)

 

(3,961)

Research and development expenses

(1,454)

 

(309)

 

(44)

 

(3,636)

 

(1,969)

 

(281)

 

* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

SO-YOUNG INTERNATIONAL INC.

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands, except for share and per share data)

 
 

For the Three Months Ended

 

For the Nine Months Ended

 

September
30
, 2023

 

September 
30
, 2024

 

September
30
, 2024

 

September
30
, 2023

 

September
30
, 2024

 

September
30
, 2024

 
 

RMB

 

RMB

 

US$

 

RMB

 

RMB

 

US$

 
             

GAAP (loss)/income from operations

(1,992)

 

4,684

 

666

 

(56,143)

 

(25,425)

 

(3,622)

 

Add back: Share-based compensation expenses

(8,759)

 

1,901

 

271

 

18,521

 

30,440

 

4,338

 

Non-GAAP (loss)/income from operations

(10,751)

 

6,585

 

937

 

(37,622)

 

5,015

 

716

 
             
             

GAAP net income attributable to So-Young International Inc.

18,305

 

20,348

 

2,897

 

3,779

 

18,049

 

2,573

 

Add back: Share-based compensation expenses

(8,759)

 

1,901

 

271

 

18,521

 

30,440

 

4,338

 

Non-GAAP net income attributable to So-Young International Inc.

9,546

 

22,249

 

3,168

 

22,300

 

48,489

 

6,911

 

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB